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Abstract: Systemic sclerosis (SSc) is an autoimmune disease characterized by vasculopathy, excessive
extracellular matrix deposition, and fibrosis of the skin and internal organs. Several infectious agents,
including human herpesvirus-6 (HHV-6), have been suggested as possible triggering factors, but a
direct association is still missing. We characterized 26 SSc patients for the presence of HHV-6 in tissues
and blood, the anti-HHV-6 response, HLA-G plasma levels, and KIR typing. Given the prominent role
of endothelial cells (EC) in SSc pathogenesis, along with HHV-6 tropism for EC, we also investigated
the expression of pro-fibrosis factors in HHV-6 infected EC. Results showed the presence of HHV-6A
in skin biopsies, and an increased virus load was associated with disease severity and poor natural
killer (NK) response against the virus, particularly in subjects exhibiting a KIR2 phenotype. HLA-G
plasma levels were significantly higher in HHV-6A/B-KIR2 positive SSc patients and in vitro HHV-6A
infection-induced pro-fibrosis factors expression in EC, supporting its role in the development of the
fibrosing process. Our data suggest an association between virus infection/reactivation and disease,
opening the way to future studies to understand the mechanisms by which HHV-6A might contribute
to the multifactorial pathogenesis of SSc.
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1. Introduction
Systemic sclerosis (SSc) is a rare autoimmune disease representing one of the most severe
connective tissue pathologies, characterized by vascular obliteration, immunological abnormalities,
and excessive extracellular matrix deposition, which causes fibrosis of the skin and of internal organs [1].
The etiopathogenesis of the disease is still unknown; possibly, multiple initial events may trigger the
release of di↵erent cytokines by inflammatory cells, di↵use microangiopathy, fibroblast activation with
abnormal collagen deposition, and subsequent ischemic and fibrotic manifestations [2].
The disease is likely a multistep and multifactorial process involving immune system alterations,
genetic, and/or environmental factors [1,3,4]; in this scenario, several infectious agents (both bacterial
and viral) have been suggested as possible triggering factors, including Parvovirus B19, human
Cytomegalovirus (CMV), Epstein Barr virus (EBV), and human herpesvirus 6 (HHV-6) [5].
HHV-6 infection is common and has a worldwide distribution [6]. The virus belongs to the  
Herpesvirinae subfamily, and two species are recognized, HHV-6A and HHV-6B, which share high
genome similarity but di↵er for some biologic properties, epidemiology, and disease association [7].
Although they are classified as lymphotropic viruses, their in vivo tropism is considerably broader,
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including T-lymphocytes, macrophages, endothelial cells (ECs), salivary glands, and brain [6,8–11],
thyroid epithelial cells [12], natural killer (NK) cells [13], and endometrial cells [14].
After primary infection, the virus establishes a latent infection, residing mainly in peripheral blood
mononuclear cells (PBMCs) and macrophages [15,16], and expressing a few specific viral transcripts
including U94, which in the absence of other viral lytic transcripts is considered a molecular marker of
viral latency [17,18].
As to the pathogenic associations, HHV-6B is the recognized etiologic agent of roseola (Exanthem
subitum), a childhood benign febrile disease, whereas HHV-6A has not yet clearly been associated with a
specific disease [19] but seems to be involved in many autoimmune diseases, especially during immune
dysregulation [20]. Virus-associated pathologies, where virus reactivation has been detected [21,22],
include autoimmune thyroiditis [12], multiple sclerosis [23–25], Sjogren syndrome [26,27], rheumatoid
arthritis and systemic lupus erythematosus [28,29], Purpura fulminans and severe autoimmune acquired
protein S deficiency [30], and severe autoimmune hepatitis [31]. However, the possible role of
HHV-6A/B infection and/or reactivation in the development of SSc is still debated.
On the immunological side, the killer immunoglobulin-like receptor KIR2DL2 has been recently
associated with a higher risk to develop SSc [32], but it is also recognized as a factor impairing
the anti-herpesviral immune response, favoring herpesvirus infection [33–35], and we observed a
consistent impaired NK response against HHV-6 in multiple sclerosis patients expressing KIR2DL2
type [25]. In parallel, we also reported that HHV-6A/B infection modulates the expression of the
tolerogenic human leucocyte antigen (HLA)-G in di↵erent cell types [36,37], and this molecule was
also reported to be di↵erentially expressed in SSc patients compared to controls, both at the skin and
blood level [38,39].
Based on these observations, this study explored the possible association between HHV-6A/B
infection and SSc development, including di↵erent sides of the hypothesis in the analysis.
We investigated the presence and replicative state of HHV-6A and 6B in SSc patients both at the blood
and tissue level, the immune responses against the virus (focusing in particular on antibody and NK
response), the host KIR type and HLA-G expression, and, as a proof of concept of HHV-6A and 6B
involvement in fibrosis induction, the ability of HHV-6A/B infection to induce an aberrant expression
of pro-fibrotic factors in vascular endothelial cells. Here, we report the results of our studies on the
possible role of HHV-6A/B infection in the pathogenesis of SSc.
2. Materials and Methods
2.1. Study Population
After approval of the study by the local Institutional Review Board and “Area Vasta Emilia Nord”
Ethical Committee (Project identification code: 2742016; 27 October 2016), 26 unselected SSc patients
(22 women and four men), all referred to the Rheumatology Unit, University-Hospital Policlinico of
Modena, Italy, were recruited. All enrolled subjects gave informed consent. The study was conducted
in accordance with the Declaration of Helsinki. All patients fulfilled the 2013 ACR/EULAR criteria for
SSc and were clinically classified according to the extent of skin involvement in limited and di↵use
SSc [40]. The mean age of SSc patients was 56 years (range 38–74 years). Clinico-epidemiological
and laboratory investigations including the modified Rodnan skin score (mRSS) to evaluate the
extent of skin fibrosis [41,42] and the main visceral organ involvement according to standardized
methodologies [1,3]. Thirty healthy subjects were included as controls (25 women and five men; mean
age 52, range 38–65). A percentage corresponding to 78.9% of patients and 75% of healthy controls
were positive for the presence of anti-HHV6 IgG antibodies, as judged from routine laboratory tests
and ELISA assay against HHV6A virus lysate.
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2.2. Clinical Samples
Heparinized peripheral blood was collected from the enrolled SSc patients and healthy controls.
In addition, cutaneous biopsies were obtained from five SSc patients and five healthy controls.
Peripheral blood mononucleated cells (PBMCs) and plasma samples were obtained by Ficoll
density gradient centrifugation (VWR International PBI, Milan, Italy) of 10 mL peripheral blood
samples. Aliquots corresponding to 5 ⇥ 105 and 106 PBMCs were pelletized and used respectively
for DNA and RNA extraction. DNA was extracted by conventional proteinase K-SDS digestion
followed by phenol-chloroform purification, as described [43]. Total RNA was extracted by the
miRNeasy kit following the manufacturer’s instructions (Qiagen, Hilden, Germany). Elimination of
contaminant DNA was assured by DNase digestions and lack of amplification in PCR reactions where
retrotranscription (RT) had been omitted [44].
Skin biopsies were frozen in liquid nitrogen immediately after collection and kept at  80  C until
use. Total DNA and RNA were extracted from biopsies respectively by the SDS-proteinase K digestion
and phenol-chloroform method and by Fibrous RNeasy kit (Qiagen, Hilden, Germany). Extracted
nucleic acids were quantified by Nanodrop spectrophotometric reading at 260/280 nm.
2.3. HHV-6 Serology
The presence of anti-HHV6A/B antibodies was verified at enrollment by a routine laboratory
test in all the subjects enrolled in the study. In addition, plasma samples from recruited patients and
healthy controls were analyzed for the presence and titer of antibodies against HHV-6A/B virus lysate
and the specific U94 virus antigen, using previously set-up ELISA assays [12,45].
2.4. Analysis of KIR Type
SSc patients and controls were analyzed for killer-cell immunoglobulin-like (KIR) type, focusing
on KIR2DL2 and KIR2DL3 receptors as they have been associated with reduced ability to control
herpesvirus infections. Briefly, DNA was extracted as described from PBMCs isolated from SSc subjects
and controls, and KIR type was analyzed by specific PCR, as previously described [46].
2.5. Virus DNA and RNA Analyses
HHV-6A/B DNA presence was analyzed by a specifically set up digital droplet polymerase chain
reaction (ddPCR), specific for the U94 gene using a QX200TM Droplet Digital TM PCR System (Biorad,
Milan, Italy) and the following set of primers and probe: HHV-6 U94(+) (50-GAG CGC CCG ATA
TTA AAT GGA T-30); HHV-6 U94(-) (50-GCT TGA GCG TAC CAC TTT GCA-3); HHV-6 U94 TaqMan
QSY probe (50-FAM-CTG GAA TAA TAA AAC TGC CGT CCC CAC C-QSY-30) (Thermo Fisher
Scientific, Milan, Italy). Amplification of the house-keeping human RNase P gene by a commercial
ready-to-use assay (Biorad, Milan, Italy) was performed as control and used to normalize virus counts
for cell number.
In positive samples, HHV-6 species identification was performed by a ddPCR specifically
discriminating 6A and 6B species, as previously described by others [47].
HHV-6A/B transcription was assessed by nested PCR and qPCR after retrotranscription (RT-qPCR),
determining the presence of lytic (U42) or latent (U94 in the absence of U42) mRNAs, as previously
described [12].
2.6. Cells and Viruses for In Vitro Virus Infection
Human umbilical vein endothelial cells (HUVEC; ATCC CRL-1730), obtained as previously
described [11,37], were grown in EGM-2 medium (BioWhittaker, Walkersville, MD, USA) in
collagen-coated plates (Biocoat Collagen, BD Biosciences, Bedford, MA, USA). All the experiments
were performed on third to fifth passage HUVECs.
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HHV-6A (U1102 strain) and HHV-6B (CV strain) stocks were respectively obtained in J-Jhan (6A)
and Sup-T1 (6B) T cells as previously described [18] and contained about 1010 genome equivalents
per ml. The same stock was used for all the experiments of infection in HUVECs. Inactivated viruses,
obtained by UV irradiation of the purified inocula for 30 min at 200 mJ/cm2, as previously described [48],
were used as controls.
2.7. Endothelial Cell In Vitro Infection
HUVECs were infected as previously described with HHV-6A (U1102 strain), HHV-6B (CV strain)
and HHV-7 (CZ strain) as a control, using a number of genome equivalents per cell corresponding
to 10:1 for all the used viruses [11]. Briefly, HUVECs were seeded at optimal density in six-well
collagen-coated plates and infected with the cell-free virus inocula for 3 h. Afterward, inocula were
removed, and fresh medium was added to the infected cells. Cells were collected 48 h post-infection
(h.p.i.), and total RNA was extracted for microarray analysis. Control cells were uninfected or infected
with the same amount of genome equivalents per cell of UV-inactivated cell-free virus inocula.
2.8. Analysis of the Expression of Fibrosis-Associated Factors
RNA from infected or uninfected HUVECs was extracted by the miRNeasy kit (Qiagen, Hilden,
Germany) as already described [44], and analyzed by a qPCR microarray simultaneously detecting 84
factors associated with fibrosis (Qiagen, Hilden, Germany). Results represented up- or down-regulation
of factors in infected versus control cells (either uninfected or infected with UV-inactivated viruses),
and were expressed as fold-change compared to values detected in control cells, after normalization
for six housekeeping genes ( actin,  2microglobulin, GAPDH, HPRT1, RPLP0, and HGDC). Duplicate
samples from three independent experiments were analyzed.
2.9. Fluorospot Assay for Immune Cell Activation
PBMCs were isolated by gradient centrifugation from peripheral blood of patients,
then 4 ⇥ 106 PBMCs were seeded in 12-well plates (1 mL/well) and cultured in RPMI supplemented
with trophic factors (PHA, IL-15, and IL-2) for 24 h. Then, NK cells were purified from PBMCs
through magnetic cell separation (MACS) system (Miltenyi Biotech, Gladbach, Germany). The NK
cell purification is an indirect magnetic labeling system for depletion of human T cells, B cells,
and myeloid cells from PBMC to enrich untouched NK cells (negative selection). Purification of NK
cells was executed according to the manufacturer’s directions. As determined by flow cytometry with
CD3-PerCp-Cy5.5, CD56-FITC moAbs (e-Bioscience, Frankfurt, Germany), the procedure resulted
in >90% pure NK cells (data non shown). Meanwhile, 96-well plates were coated overnight with
HHV-6A/B lysate or purified U94 protein (2 µg/mL). Purified NK cells (2 ⇥ 105 cells/100 µL/well)
were then assayed for the ability to recognize and being activated by HHV-6A/B and U94, measuring
IFN  and Granzyme B production. The release of IFN-  and Granzyme B by stimulated NK cells
was assayed by Fluorospot assay (Thermo Fisher Scientific, Milan, Italy), following the manufacturer
instructions. The measurement was performed by reading fluorescence by the automated microplate
reader Infinite M200, Tecan (Austria GmbH, Grodig, Austria) equipped with filters for excitation
490 nm/emission 510 nm (FITC) for 490-reagent detection and excitation 550 nm/emission 570 nm (Cy3)
for 550-reagent detection.
2.10. Analysis of HLA-G in Patients’ Blood
Plasma samples derived from whole blood after density centrifugation were analyzed for HLA-G
presence by ELISA assay, as previously described [49]. Briefly, sHLA-G plasma levels were measured
by an enzyme-linked immunosorbent assay (ELISA) in duplicate according to the Essen workshop
(Rebmann et al., 2005). Briefly, 96-well plates were coated with the capture antibody MEM-G9 MoAb
(Exbio, Praha, Czech Republic) and the presence of sHLA-G was revealed using anti- 2 microglobulin
MoAb—HRP as the detection antibody.
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2.11. Statistical Analyses
Statistical analyses were performed by Mann–Whitney and Fisher tests. Student’s t-test with the
Bonferroni correction for multiple comparisons was used for comparison between infected and control
cells (microarray data). A corrected p (pc) value  0.05 was considered significant.
3. Results
3.1. HHV-6 Detection in SSc Patients
The demographic, clinical, and serological features of the 26 SSc patients and healthy control
subjects enrolled in the study are summarized in Table 1.
Table 1. Demographic and clinical features of the study population.
Parameters SSc Patients Controls
Number 26 30
Age (median, range) 56 (37–74) 52 (38–65)
Gender
Male (n, %) 4 (15.4%) 5 (16.6%)
Female (n, %) 22 (84.6%) 25 (83.3%)
HHV-6 Ab (n, %) 20 (76.9%) 22 (73.3%)
Disease duration (median years, range) 5 (1–20) -
mRSS (median, range) 7 (0–33) -
Cutaneous subgroups
Di↵use cutaneous SSc 5 (19.2%) -
Limited cutaneous SSc 21 (80.7%) -
Clinical signs (n, %)
Raynaud’s phenomenon 26 (100%)
Digital ulcer 10 (38.5%) -
Pu↵y fingers 14 (53.8%) -
Pitting 8 (30.7%) -
Telangiectasia 13 (50%) -
Arthralgia 13 (50%) -
Interstitial lung disease 15 (57.7%) -
Heart involvement 1 (3.8%) -
Esophageal dysfunction 13 (50%) -
Autoantibodies (n, %)
Positive ANA 25 (96.1%) -
Positive ACA 9 (34.6%) -
Positive anti-Scl70 9 (34.6%) -
Treatments (n, %) *
Steroids 3 (11.5%) -
Immunosuppressors 3 (11.5%) -
Prostanoids 19 (73.1%) -
Bosentan 7 (26.9%) -
Calcium antagonist 18 (69.2%) -
mRSS: modified Rodnan skin score; ANA, anti-nuclear autoantibodies; ACA, anti-centromere auto-antibodies;
anti-Scl70, anti-topoisomerase type of anti-nuclear antibodies. * Ongoing treatment at the time of patients’
recruitment;   mycophonolate mofetil.
From each subject, peripheral blood was collected and analyzed for the presence of HHV-6A/B,
performed by ddPCR designed in the conserved U94 gene and detecting both species. The raw copy
number was normalized for the cell number, as detected by the RNaseP copy number, and expressed as
the virus genome copy number per 106 cells. The results evidenced that HHV6A or 6B were detectable
in a high proportion of PBMCs from SSc patients (21/26, 80.7%) compared to healthy controls (12/30,
40%) (p < 0.001) (Figure 1A), and that viral load was significantly higher in the SSc group (median
copy number 235.5, range 19–550 per 106 cells) with respect to healthy subjects (mean copy number
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18.9, range 18–224 per 106 cells) (p < 0.0001). Indeed, as judged by ddPCR results, 61.9% of samples
derived from SSc PBMCs had >100 copies of HHV6A/B genomes per 106 cells, whereas only 30% of
PBMCs from control group contained >100 copies of virus genomes per 106 cells.
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Figure 1. Presence of HHV-6A/B at the blood and skin level in sclerodermic patients and controls.
patients. Total DNA extracted from peripheral blood mononuclear cells (PBMCs) (A) or skin tissue
biopsies (B) was extracted and analyzed by a digital droplet polymerase chain reaction (ddPCR) for
U94, detecting both virus species. Marks represent the mean values of duplicate samples from each
individual; mean line and standard deviation (SD) values are also shown. SSc, systemic sclerosis
patients; CTR, controls.
The analysis of HHV-6A/B at the tissue level, performed by ddPCR on skin biopsies, evidenced
the presence of virus DNA in all the SSc collected samples, although with di↵erent loads (Figure 1B).
The mean genome copy number was 315 per 106 cells (range 86–570), and 4/5 samples (80%) contained
more than 100 copies/106 cells. No skin samples from healthy controls had detectable levels of
HHV-6A/B (p < 0.005 by paired t-test).
The species identification, performed in each HHV-6A/B positive sample by a specific ddPCR
discriminating the two virus species, evidenced that species 6A was prevalent in the skin tissue,
although 6B was also detectable at a low level; whereas species 6B was almost exclusively harbored in
PBMC samples (Figure 2).
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Figure 2. Prevalence of HHV-6A and HHV-6B species at the blood and skin level in SSc patients. Total
DNA extracted from skin tissue biopsies (A) or PBMC from peripheral blood (B) was extracted and
analyzed by ddPCR discriminating between the two virus species. Results are expressed as genome
copy number per µg of DNA, and represent the mean values of duplicate samples. Mean line and SD
values are also shown.
Next, we analyzed the virus transcriptional state in the HHV-6A/B positive skin and PBMC
specimens. Two virus genes were tested: U94, as the detection of its transcripts, in the absence of other
early transcripts, is indicative of latent infection, and U42, as its transcription is indicative of productive
infection. The transcriptional analysis, performed by nested PCR and qPCR after retrotranscription
(RT-qPCR) on all HHV-6-positive samples, evidenced productive replication in two out of five biopsies
(2/5, 40%), where U42 transcripts were detected in addition to U94 ones, although at very low levels
(<100 copies per 106 cells) (Figure 3). The two U42-positive biopsies were also those harboring the
highest virus load, as detected by ddPCR. By contrast, the analysis of the transcriptional state of the
HHV6 in PBMCs evidenced the only transcription of U94 gene in both SSc and control PBMCs, with no
concurrent transcription of U42 (used as a marker of productive infection), suggesting that the virus
was latent in all samples, at least at the moment of the withdrawal (not shown).
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Figure 3. HHV-6A/B replicative state in skin biopsies. Virus transcription was ev luated by nested PCR
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refer to the amplification of U94 and 42 virus genes, and the human ho se-keeping  -acti ene as
a control. MW, Molecular Weight marker; B, blank; C-, negative control; C+, positive control; b1–5,
biopsy 1–5.
3.2. HHV-6 Serology of SSc Patients
Enrolled SSc patients were characterized for anti-HHV-6 antibody seropositivity by routine
laboratory analyses, showing a high prevalence of positive subjects (76.9%), as expected based on the
high prevalence of HHV-6A/B infection in the general population. No statistically significant di↵erent
prevalence or titer was observed in the SSc group compared to the control group (p=n.s.), similar to what
was reported previously for other autoimmune pathologies (Figure 4A). However, based on previous
observations evidencing potentially significant di↵erences in the antibodies specifically directed against
the U94 virus antigen, even in the absence of significant di↵erences in the anti-HHV-6A/B antibody
prevalence or titer [12,45], we analyzed the antibody response against U94 in the SSc patients cohort
(Figure 4B). The results showed both a di↵erent prevalence and titer of the anti-U94 antibodies in the
SSc group compared to the healthy controls (p < 0.004), as the presence of anti-U94 antibodies was
detected in 26/26 (100%) of the SSc patients and in 14/30 (46.7%) of the healthy subjects; in addition,
their titer was significantly higher in the SSc group (median titer 1:403, range 1:100–800), whereas
control group displayed a mean titer corresponding to 1:166 (range 1:50–400), confirming previous
results [45].
Since we have already observed that HHV-6A U94 can induce HLA-G in HUVEC cells, inhibiting
angiogenesis [37], we analyzed HLA-G plasma levels in correlation with HHV-6A/B presence in SSc
patients. As shown in Figure 5, we observed an increase in plasmatic HLA-G in HHV-6 positive
patients, compared to HHV-6 negative ones (p < 0.0001). Furthermore, the positivity for HLA-G and
HHV-6 also correlated with the anti-U94 antibody titer (p < 0.05), as HLA-G/HHV-6 positive patients
exhibited the highest anti-U94 IgG plasma levels (p < 0.05).
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differences were observed between SSc patients and controls with regard to response against virus 
lysate (not shown). By contrast, as summarized in Figure 6, an impaired NK activity in SSc subjects 
compared to controls was observed toward the U94 virus antigen, although the difference was not 
statistically significant (Figure 6A). Notably, the difference was significant when subdividing SSc 
patients for virus positivity or negativity (as detected by ddPCR), with a clear impairment of NK 
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Figure 5. HLA-G plasma levels in SSc patients. (A) Level of circulating sHLA-G in plasma of HHV-6A/B
negative and positive SSc patients (**, p < 0.0001). (B) Correlation between HHV-6/HLA-G positivity
and anti-U94 antibody titer in SSc patients (*, p < 0.05). Results are reported as mean values ± SD.
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3.3. KIR Typing in SSc Patients
We previously observed that specific killer-cell immunoglobulin-like (KIR) receptors expressed
in natural killer (NK) cells are associated with increased susceptibility to multiple herpesvirus
reactivations [25,46]. Thus, SSc patients were characterized for the prevalence of KIR2DL2 and
KIR2DL3 types. The results showed no statistically significant di↵erences in the prevalence of DL2 and
DL3 types in the SSc group compared to controls, with distribution values in line with data obtained
in the general population, although homozygosity for DL2 was slightly higher in our control cohort
compared to literature data on healthy population (3.3% vs. 1.2%) [46] (Table 2).
Table 2. Distribution of KIR2-DL2 and KIR2-DL3 types in systemic sclerosis (SSc) patients and
healthy subjects.
KIR Type SSc Patients (n = 26) Controls (n = 30)
DL2/DL2 1 (3.8%) 1 (3.3%)
DL2/DL3 8 (30.8%) 11 (33.7%)
DL3/DL3 17 (65.4%) 18 (60%)
3.4. NK Response against HHV-6 in SSc Patients
NK immune response is crucial for the control of herpesvirus infection. Since we previously
observed a defect in NK control in di↵erent autoimmune disorders associated with HHV-6A/B infection,
we analyzed such a response in SSc patients. In this respect, a Fluorospot assay was performed
using NK purified from PBMCs isolated from peripheral blood. Briefly, cultured PBMCs were used
to purify NK cells, which were assayed for the ability to recognize and be activated by HHV-6A/B
and U94, measuring IFN  and Granzyme B production. No statistically significant di↵erences were
observed between SSc patients and controls with regard to response against virus lysate (not shown).
By contrast, as summarized in Figure 6, an impaired NK activity in SSc subjects compared to controls
was observed toward the U94 virus antigen, although the di↵erence was not statistically significant
(Figure 6A). Notably, the di↵erence was significant when subdividing SSc patients for virus positivity
or negativity (as detected by ddPCR), with a clear impairment of NK activity in the HHV-6A/B positive
versus negative SSc subjects (Figure 6B). Moreover, among HHV-6A/B positive subjects a statistically
significant di↵erence was also observed between groups of SSc patients with a high (>100 copies/µg
DNA) or low (<100 copies/µg DNA) virus load at the tissue level (Figure 6C) (p < 0.05), with the highest
impairment of NK activation observed in SSc subjects positive for virus presence and displaying
simultaneously a KIR2DL2 haplotype (p < 0.0001) (Figure 6D). By contrast, no significant di↵erences
were observed in IFN  production (data not shown).
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Figure 6. Anti-HHV-6 NK activity in SSc patients. PBMCs isolated from peripheral blood were assayed
by Fluorospot for the NK ability to be activated by HHV-6 and U94. (A) Natural killer (NK) activation
(Granzyme B production) in SSc patients and controls; (B) NK activation in SSc patients subdivided for
HHV-6A/B positivity or negativity; (C) NK activation i HHV-6 positive SSc patients subdivided for
HHV-6 loa at the tissue level; (D) NK activation in SSc patients subdivided for HHV-6A/B skin load
and KIR2DL2 presence. Results are expr ssed as mean value ± SD of duplicate samples (*** p < 0.0001;
* p < 0.05).
3.5. HHV-6 Induction of Fibrosis-Associated Factors in Endothelial Cells
Third to fifth passage human primary ECs were infected with cell-free inocula of HHV-6A and
HHV-6B, or with the correspondent UV-inactivated viruses. The e ciency of infection was about
50%, and productive replication took place in the first week post-infection, as already previously
described [11] (not shown). Analysis of the expression of pro-fibrosis factors, performed by microarray
on RNA extracted from infected cells, showed that HHV-6A/B infection can induce the transcription
of diverse factors potentially impacting fibrosis development. In particular, after 48 h, 10 factors out
of the 84 analyzed appeared to be altered by one or both HHV-6 species (Supplemental Figure S1),
whereas no factors were a↵ected by the UV-inactivated viruses used as controls. In detail, both virus
species highly up-regulated the expression of the pro-fibrotic factors GREM1 and IL5 (>90 fold by
HHV-6A and >60 fold by HHV-6B), and also upregulated to a less extent INHBE, MMP9 and TNF (up
to 7.79 fold by HHV-6A and up to 9.35 fold by HHV-6B), while IL4 was upregulated by HHV-6A only
(19.89 fold). In parallel, some anti-fibrotic factors were also induced, including SMAD6 and SMAD7
(upregulated only by HHV-6A), STAT1 (induced by both HHV-6A and 6B species), and hepatocyte
growth factor (HGF) (by HHV-6B only) (Figure 7).
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Figure 7. Induction of fibrosis-associated factors by HHV-6A/B infection in human endothelial cells
(HUVEC). The modulation of factors potentially associated with fibrosis development was assayed in
uninfected HUVEC (CTR) or in HUVEC infected in vitro with HHV-6A, HHV-6B, or the respective
UV-inactivated viruses, used as controls. Total RNA was extracted 48 h post-infection and analyzed by
a microarray quantifying simultaneously 84 factors associated with fibrosis. Factors modulated by virus
infection are shown. Results are expressed as mean values of duplicate samples in three independent
experiments ± SD of fold-change compared to values detected in controls (CTR), after normalization
for six housekeeping genes ( -actin,  2-microglobulin, GAPDH, HPRT1, RPLP0, and HGDC).
4. Discussion
Systemic sclerosis (SSc) is a connective tissue disease of unknown etiology, characterized by
complex immune system alterations and di↵use microangiopathy and fibrosis of the skin and visceral
organs. The etiopathogenesis of SSc may include di↵erent environmental factors, among which
are microbial infections. In this scenario, infection by HHV-6A/B has been suggested as a potential
causative co-factor of the disease, but a definite role has not been established. The same virus has been
long associated with di↵erent autoimmune conditions involving di↵erent cell types and tissues [50],
such as autoimmune thyroiditis [12] that is frequently observed in SSc patients. On the other hand, we
also reported that the virus can be detected in endothelial cells in vivo [51], and can infect endothelial
cells in vitro, exhibiting a potent anti-angiogenetic activity [11].
Based on these observations, our study analyzed virological and immunological footprints of
HHV-6A/B infection in SSc patients, also investigating the ability of the virus to induce, in vitro in
endothelial cells, the expression of pro-fibrotic factors that could potentially be associated with the
development of the disease in vivo.
The results of our investigations showed a significantly higher prevalence of HHV-6A/B DNA
in both blood and peripheral tissues of SSc patients compared to controls. In particular, the virus
was detectable in 80.7% of PBMCs from SSc patients and in only 40% of healthy controls (p < 0.001),
and the virus load was significantly higher in the SSc group (median copy number 235.5 per 106 cells)
compared to healthy subjects (median copy number 18.9 per 106 cells) (p < 0.0001). However, the
results identified a split population in SSC group, one harboring high virus load and the other with
low/no virus, suggesting that HHV-6A/B may contribute to the disease in a subgroup of patients,
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similarly to what observed in multiple sclerosis [25]. Indeed, at the skin level, the di↵erences were
particularly significant; in fact, although the number of skin biopsies available for the analyses was low,
five out of five SSc specimens were positive for the presence of HHV-6A/B DNA, whereas no samples
derived from healthy skin had detectable amounts of the virus. In the cutaneous biopsies, the species
6A was the most represented, consistent with previously reported data on HHV-6A tropism [52],
whereas HHV-6B was present almost exclusively in PBMC, confirming as well previous reports [52,53].
Due to the small dimension of skin biopsies, it was not possible to perform immunochemistry to detect
HHV-6A/B antigens, but this could be important in future studies, to verify virus presence.
Importantly, higher virus loads correlated with the severity of scleroderma cutaneous and internal
organ involvement, as well as with the presence of worse immunological markers (anti-Scl70 antibodies).
In fact, both anti-U94 antibody titer and NK impairment against HHV-6A/B appeared increased in the
SSc subgroup displaying high virus load in PBMC and skin. Moreover, the impairment of NK response
against the virus was particularly evident and significant in patients expressing KIR2DL2 receptors,
as already reported in other autoimmune conditions associated with HHV-6 infection [25], confirming
that HHV-6A might express its full pathogenic potential in KIR2DL2 subjects.
Although a similar prevalence of anti-HHV-6A/B antibodies in the SSc group and healthy
controls (76.8 vs. 75%), the prevalence and titer of anti-U94 antibodies were significantly higher
in the SSc population (100%, median titer 1:400) compared to controls (46.7%, median titer 1:166)
(p < 0.004), confirming previous similar observations in multiple sclerosis patients [45]. Furthermore,
consistently with previous observations showing the ability of virus infection to inhibit angiogenesis by
a U94-mediated sHLA-G production in endothelial cells [37], we detected increased levels of sHLA-G
in HHV-6A/B positive SSc patients compared to negative ones (p < 0.0001). Notably, SSc patients who
were both HHV-6A/B and HLA-G positive, also displayed the highest titer of anti-U94 antibodies
(p < 0.05), supporting a possible role of HHV-6A/B infection in the disease progression.
As proof of concept, we analyzed whether HHV-6 infection could induce pro-fibrotic molecules
expression in endothelial cells. Endothelial injury represents, in fact, one of the first steps in the
pathogenesis of SSc, predominantly a↵ecting the microcirculation [54]. Aiming to clarify this aspect,
HUVEC were infected in vitro with HHV-6A or 6B, and analyzed for the expression of a panel of 84
fibrosis-associated factors. The results showed that HHV-6A and 6B infection induced the upmodulation
of several factors, suggesting that infection per se may interfere with the normal functions of endothelial
cells [11,37]. Although the TGF 2 factor, recently recognized as a key factor in fibrosis induction, did
not result upregulated by virus infection in HUVECs, other factors belonging to TGF  superfamily
were promoted in particular by HHV-6A, including GREM1 and INHBE, IL-4, IL-5, TNF, and MMP9.
Many of such virus-induced factors have been reported as key factors in tissue fibrosis: GREM1 was
recognized as a key pro-fibrotic factor in renal, pancreatic, and pulmonary fibrosis [55–57]; INHBE,
a member of the TGF  superfamily of proteins, was reported to be associated with dermal fibrosis [58];
IL-4 is even more active than TGF  in inducing collagen synthesis in human skin fibroblasts [59,60],
and can drive fibroblast di↵erentiation and promote pro-fibrotic macrophages activation [61]. IL-5also
plays an important role in promoting tissue fibrosis [60,62]; and TNF antagonists are beneficial for the
treatment of fibrotic disorders, supporting a pro-fibrotic role of TNF [41,63–65]. By contrast, the role
of MMP9 is unclear, having a pro-fibrotic or anti-fibrotic action in di↵erent rodent models [66,67].
Some anti-fibrotic factors, namely SMAD6, SMAD7, STAT1, and HGF, were also induced by the virus
infection, although to a lesser extent compared to pro-fibrotic upregulation, perhaps as a counterbalance
of the potent pro-fibrotic expression induced in vitro by virus infection.
Consistent with our findings, endothelial progenitor cells (EPC) with impaired angiogenic function
have been detected in peripheral blood of SSc subjects [68], and the regression of capillaries and small
vessels during SSc strongly suggests an impairment in the angiogenetic abilities of endothelial cells,
although the specific mechanisms have not yet been elucidated.
It is conceivable that multiple triggering and predisposing genetic factors can variably contribute
to both di↵use microangiopathy and fibrosis observed in SSc, according to the di↵erent stages of the
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disease [69–73] and di↵erent SSc subsets [1,3]. In this respect, the observed increased sHLA-G plasma
levels and titer of anti-U94 antibodies in SSc subjects might be considered a marker for disease severity
and suggest the involvement of the virus and U94 in the development of the disease.
Although several studies provided important information linking infectious agents to SSc, a direct
association is still missing. Our virological and immunological data suggest that HHV-6A/B, and in
particular the 6A species, might have a role in the disease onset and/or progression and open the way
for future studies aimed to confirm these data in a higher number of subjects and focusing on the
mechanisms by which viral products might synergize with other factors (82-86), ultimately favoring
the SSc development.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-2607/8/1/39/s1,
Figure S1: Induction of fibrosis-associated factors by HHV-6A/B infection in human endothelial cells (HUVEC).
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